Shots:
- LEO Pharma has entered into a definitive agreement to acquire Replay, expanding its dermatology pipeline with Replay’s herpes simplex virus-based gene therapy platform for rare genetic skin disorders
- As per the deal, LEO will acquire Replay for $50M upfront, plus milestone payments & tiered single-digit royalties, while adding Replay’s HSV design and manufacturing expertise to LEO Pharma’s next-generation dermatology portfolio
- Replay’s engineered HSV platform delivers large therapeutic genes directly to skin cells through a topical gel, with its lead preclinical candidate targeting dystrophic epidermolysis bullosa
Ref: Businesswire | Image: Replay | Press Release
Related News: LEO Pharma’s Enstilar Receives the NMPA Approval for Plaque Psoriasis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
